| Document |
Document Title |
|
JP2016115584A |
To provide a power storage material capable of being suitably used as an active material for a power storage device, particularly for a lithium ion secondary battery, and furthermore, to provide a power storage device for exhibiting char...
|
|
JP5887300B2 |
|
|
JP2016507569A |
The present invention relates to novel crystalline salt lamivudine, methods of its preparation, pharmaceutical compositions thereof, and its use in the treatment of viruses such as human immunodeficiency virus (HIV) infection. In one asp...
|
|
JP2015227325A |
To provide a novel pest control agent, particularly insecticide or miticide.The present invention provides a pyrazole or thiazole derivative represented by formula (1) or salt thereof. [Arepresents -N(O)or -CR; Rrepresents H, a halogen a...
|
|
JP5806417B2 |
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (M...
|
|
JP5769700B2 |
The present invention provides a novel amino compound that blocks the I Kur current or the Kv1.5 channel potently and more selectively than other K + channels. The present invention relates to an amino compound represented by General For...
|
|
JP2015145423A |
To provide cannabinoid receptor modulators.The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CBreceptor. The present invention further r...
|
|
JP5755220B2 |
Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.
|
|
JP5746698B2 |
The present invention relates to certain compounds of Formula la and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula la...
|
|
JP5745406B2 |
The invention relates to substituted aminoindanes and analogs thereof of formula I and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders su...
|
|
JP5735482B2 |
Provided herein are compounds of Formula I, pharmaceutical compositions comprising the same, and combination therapies comprising the same for treatment of hepatitis C.
|
|
JP5735799B2 |
GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:wherein R1a, R1b, R1c, R1d, R2, R2a, and...
|
|
JP5690731B2 |
Single enantionmers of compounds of formula (B), in either the cis or trans configuration, wherein R1 and R2 are as defined herein, can be separated from enantiomeric mixtures thereof by reacting the compound with an acid to produce a co...
|
|
JP2015028045A |
To provide preparation and isolation of novel polymorphic (-)-(cis)-FTC [(4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)
-2-(1H)-pyrimidinone)(2R-cis) or β-L-2-hydroxymethyl-5-(5-fluoro-cytosin-1-yl)-1,3-oxathiola
ne].Crysta...
|
|
JP2014532680A |
The present invention relates to the use of known pyridylcarboxamide derivatives as nematode killing agents, compositions containing such compounds, and methods of controlling nematodes.
|
|
JP5613780B2 |
Lamivudine oxalate, preparation method and crystalline forms thereof are disclosed. A preparation method of Lamivudine is also disclosed.
|
|
JP5577251B2 |
The present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivatives thereof. The present invention also relates to novel 2-substituted 4-substituted 1,3-oxathiolanes ...
|
|
JP5566255B2 |
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment o...
|
|
JP5547772B2 |
Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base....
|
|
JP5538528B2 |
The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to ...
|
|
JP5529010B2 |
Fixed combination, non-fixed combination or kit of parts comprising 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihy
dro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2
,5-dione, pioglitazone or a pharmaceutically ac...
|
|
JP5513515B2 |
Compounds of formula (I), wherein X, Z, A, B, D, E, R1-R4 and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2 antagonists.
|
|
JP5479324B2 |
The present invention discloses a process for stereoselective synthesis of Lamivudine comprising the following steps: (a) performing a glycosylation reaction between the compound of formula (I) and cytosine or protected cytosine, and sep...
|
|
JP5347072B2 |
Disclosed are compounds exhibiting sufficient herbicidal activity at low application dosage when they are applied to soils and foliage, and an agrochemical composition using the same, in particular herbicides. The compounds are triazine ...
|
|
JP5315299B2 |
The present invention relates to a compound which is 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1 H -benzo[ d ]azepin-7-yloxy)- N -methyl-nicotinamide or a pharmaceutically acceptable salt thereof. This compound and its pharmaceutically acceptab...
|
|
JP5304653B2 |
Disclosed is an organic electroluminescent device having high emission luminance and low driving voltage. Also disclosed are an illuminating device and a display device each using such an organic electroluminescent device. The organic el...
|
|
JP5261482B2 |
The present invention provides a novel nitrogen-containing heterocyclic compound and salt thereof, and a fungicide for agricultural and horticultural use that contains at least one thereof as an active ingredient, demonstrates reliable e...
|
|
JP5255765B2 |
A novel process for preparing emtricitabine, and more particularly a process for preparing emtricitabine involving the formation and isolation of intermediate compounds in salified form, is described.
|
|
JP5241834B2 |
The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said...
|
|
JP2013528180A |
The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositio...
|
|
JP2013526484A |
Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.
|
|
JP2013521250A |
The instant invention relates to derivatives of formula (I) and their application in therapeutics.
|
|
JP5203897B2 |
Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base....
|
|
JP2013519676A |
A thermodynamically controlled process for preparing Form I polymorph of lamivudine is described, wherein the process involves crystallizing Form I at a temperature of from about 0° C. to about 50° C. from a mixture which comprises (a)...
|
|
JP5187592B2 |
The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the sal...
|
|
JP5184511B2 |
The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (−) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyr
imidin-2-one in the form of mon...
|
|
JP2013049692A |
To provide a novel heterocyclyl ethyl carboxamide derivative and a fungicide composition containing the derivative which is useful as a fungicide for a pesticide.The heterocyclyl ethyl carboxamide derivative is represented by general for...
|
|
JP5159605B2 |
A compound of general formula (I) : A process for preparing this compound. A fungicide composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition ...
|
|
JP2013040192A |
To provide new polymorphic and other crystalline forms of FTC, to provide a new method for preparing and isolating polymorphic and other crystalline forms of FTC and to provide a use of FTC polymorphic body, FTC of other phases and treat...
|
|
JP2013010773A |
To provide a prodrug including an NO-releasing prodrug a double prodrug, and mutual prodrug, in which bio-cleavable linker and a remedy are linked covalently.There is provided a compound of formula (I) or a pharmaceutically acceptable sa...
|
|
JP5105689B2 |
Solid phases of (-)-cis-FTC, which are designated herein as amorphous (-)-FTC and Forms II and III (-)-cis-FTC) are provided that can be distinguished from Form I (-)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and ...
|
|
JP2012230356A |
To provide a resist composition from which a pattern having an excellent mask error factor can be obtained.The resist composition contains: a compound expressed by the formula (I); a resin which has an acid-labile group, is insoluble or ...
|
|
JP5031565B2 |
The present invention is directed to compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation o...
|
|
JP5015586B2 |
Compounds of formula (I): wherein: R<2> is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, ...
|
|
JP5001254B2 |
There is provided a method for resolving a compound of formula (III), in the cis configuration: There is also provided a process for producing optically active compound of formula (I) or (II): wherein: R1, R2, R3 are as defined herein, t...
|
|
JP2012136526A |
To provide a method for producing a compound having cis stereoconfiguration and represented by formula I, and an optically active form thereof.Production, recovery and conversion of a diastereomer salt of the compound are provided.
|
|
JP4966886B2 |
|
|
JP4931600B2 |
A compound of general formula (I) A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a c...
|
|
JP4921375B2 |
Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, OR...
|
|
JP4911860B2 |
The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -a1-a2-a3-a4- is a bivalent radical wherein on...
|
